stockrow
Friday 6 November 2026
Export ARQT’s income statement to Excel — free account
Arcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024.
- Revenue
- +45.1%
- EPS
- +12.0%
- Free cash flow
- +1,171.9%
- Total debt
- +0.83%
Quarter to September 2026, against a year earlier
25.55
1.45
−5.37%
Follow ARQT
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 119.18 | 116.33 |
P/S ratio |
9.82 | 7.33 | 7.38 | 6.81 | |
P/FCF ratio |
0.00 | 269.53 | 142.16 | 77.45 | |
P/Operating CF |
141.11 | 1,361.25 | 270.77 | 183.23 | |
P/B ratio |
19.50 | 16.07 | 15.52 | 14.19 | |
Price to Tangible BV |
21.15 | 17.38 | 16.54 | 15.00 | |
EV/Sales |
9.53 | 7.06 | 7.10 | 6.51 | |
EV/EBITDA |
0.00 | 724.90 | 92.59 | 89.88 | |
EV/Operating CF |
(636.90) | 108.65 | 83.76 | 55.24 | |
EV/FCF |
(168.11) | 259.37 | 136.76 | 74.09 | |
Quick Ratio |
2.83 | 2.26 | 2.46 | 2.50 | |
Current Ratio |
3.17 | 2.68 | 2.92 | 2.92 | |
Net Debt/EBITDA |
(5.92) | 13.19 | (7.75) | (15.30) | |
Debt/Assets |
25.17% | 23.79% | 22.29% | 20.86% | |
Debt/Equity |
0.58 | 0.58 | 0.49 | 0.45 | |
Asset Turnover |
0.96 | 1.03 | 1.10 | 1.14 | |
Operating CF/Net income |
1.51 | (0.20) | 0.84 | 2.15 | |
Capex/Depreciation |
0.00 | 0.00 | (0.46) | (0.25) | |
Interest Coverage |
6.13 | (2.08) | 4.82 | 3.19 | |
Research and Development Expense of Revenue |
15.79% | 29.06% | 15.67% | 15.58% | |
Selling, General and Administrative Expense of Revenue |
60.98% | 70.28% | 63.25% | 69.21% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
7.77% | 10.14% | 9.83% | 8.59% | |
Graham Net Nets |
0.05 | 0.06 | 0.06 | 0.06 | |
Graham Number |
0.00 | 0.00 | 2.89 | 3.09 | |
Earnings Yield |
(0.45%) | (0.08%) | 0.84% | 0.86% | |
Free Cash Flow Yield |
(0.58%) | 0.37% | 0.70% | 1.29% | |
Revenue per Share |
1.02 | 0.81 | 0.99 | 1.10 | |
Operating CF per Share |
0.21 | 0.02 | 0.10 | 0.14 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.21 | 0.02 | 0.10 | 0.14 | |
Cash per Share |
1.74 | 1.73 | 1.83 | 1.98 | |
Shareholders Equity per Share |
1.49 | 1.47 | 1.69 | 1.86 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.49 | 1.47 | 1.69 | 1.86 | |
Free Cash Flow |
26.19 | 2.24 | 12.48 | 18.80 | |
Working Capital |
281.39 | 274.85 | 307.33 | 331.33 | |
Capital Expenditures |
0.00 | — | (0.16) | (0.10) | |
Net Current Asset Value |
167.74 | 167.70 | 199.71 | 223.23 | |
EV/EBIT |
0.00 | 912.84 | 96.12 | 94.20 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 948.60 | 99.91 | 98.47 | |
| Other line items | |||||
Average Receivables |
109.65 | 114.90 | 130.93 | 143.20 | |
Average Payables |
13.37 | 21.41 | 10.84 | 7.07 | |
Average Inventory |
18.58 | 27.00 | 27.60 | 34.04 | |
Average Assets |
390.93 | 402.05 | 420.49 | 447.70 | |
Average Common Equity |
173.51 | 166.15 | 179.78 | 201.02 |
Columns are period end dates · fundamentals updated 6 Nov 2026